Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Antoine Finianos & Jeanny B. Aragon-Ching. (2019) Zoledronic acid for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 20:6, pages 657-666.
Read now
Read now
Nancy A Dawson. (2003) Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease. Expert Opinion on Pharmacotherapy 4:5, pages 705-716.
Read now
Read now
Articles from other publishers (26)
Jindal Arun & Jindal Puja. (2017) A PROSPECTIVE STUDY TO EVALUATE THE EFFECTS OF SODIUM ALENDRONATE (AN ORAL BISPHOSPHONATE) ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH CARCINOMA PROSTATE TREATED WITH HORMONAL MANIPULATION. Journal of Evolution of Medical and Dental Sciences 6:29, pages 2387-2390.
Crossref
Crossref
KOGENTA NAKAMURA, YOSHIAKI YAMADA, CHARLES J. ROSSER, MAKI ARAKAWA, KENJI ZENNMAI, YOSHIHARU KATO, MASAHITO WATANABE, REMI KATSUDA, MOTOI TOBIUME, KATSUYA NARUSE, SHIGEYUKI AOKI, TOMOHIRO TAKI, HIROKO SAITO, TAKAAKI HASEGAWA & NOBUAKI HONDA. (2010) The use of zoledronic acid in Japanese men with stage D2 prostate cancer. Oncology Letters 1:1, pages 13-16.
Crossref
Crossref
T. Lebret & A. Méjean. (2008) Physiopathologie, diagnostic et prise en charge des métastases osseuses du cancer de prostate. Progrès en Urologie 18, pages S349-S356.
Crossref
Crossref
Noel W. Clarke & Herbert A. Fleisch. 2007. Metastasis of Prostate Cancer. Metastasis of Prostate Cancer
253
281
.
Noel W. Clarke. (2006) Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis. European Urology Supplements 5:17, pages 873-876.
Crossref
Crossref
Noel W. Clarke. (2006) New Clinical Tools for Urologists: Treatment of Bone Loss. European Urology Supplements 5:17, pages 877-879.
Crossref
Crossref
Özlem Daltaban, Işıl Saygun & Erol Bolu. (2006) Periodontal Status in Men With Hypergonadotropic Hypogonadism: Effects of Testosterone Deficiency. Journal of Periodontology 77:7, pages 1179-1183.
Crossref
Crossref
Fred Saad, Noel Clarke & Marc Colombel. (2006) Natural History and Treatment of Bone Complications in Prostate Cancer. European Urology 49:3, pages 429-440.
Crossref
Crossref
Mayank M. Agarwal, Niranjan Khandelwal, Arup K. Mandal, Satyawati V. Rana, Vivek Gupta, Vaddi Chandra Mohan & Gottapu V. M. K. Kishore. (2005) Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer 103:10, pages 2042-2052.
Crossref
Crossref
J. A. Kiefer, R. L. Vessella, J. E. Quinn, A. M. Odman, J. Zhang, E. T. Keller, P. J. Kostenuik, C. R. Dunstan & E. Corey. (2004) The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical & Experimental Metastasis 21:5, pages 381-387.
Crossref
Crossref
Martine P. Roudier, Eva Corey, Lawrence D. True, Celestia S. Hiagno, Susan M. Ott & Robert L. Vessella. 2004. The Biology of Skeletal Metastases. The Biology of Skeletal Metastases
311
339
.
F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J. L. Chin, J. J. Vinholes, J. A. Goas & B. Chen. (2002) A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma. JNCI Journal of the National Cancer Institute 94:19, pages 1458-1468.
Crossref
Crossref
Alfredo Berruti, Marcello Tucci, Carlo Terrone, Gabriella Gorzegno, Roberto M. Scarpa, Alberto Angeli & Luigi Dogliotti. (2002) Background to and Management of Treatment-Related Bone Loss in Prostate Cancer. Drugs & Aging 19:12, pages 899-910.
Crossref
Crossref
Terrence H. Diamond, Julie Winters, Angie Smith, Paul De Souza, John H. Kersley, William J. Lynch & Carl Bryant. (2001) The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer 92:6, pages 1444-1450.
Crossref
Crossref
Harry W Daniell. (2001) Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 58:2, pages 101-106.
Crossref
Crossref
AXEL HEIDENREICH, RAINER HOFMANN & UDO H. ENGELMANN. (2001) THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER. Journal of Urology 165:1, pages 136-140.
Crossref
Crossref
Stephen B. Strum, Mark C. Scholz & Jonathan E. McDermed. (2000) Intermittent Androgen Deprivation in Prostate Cancer Patients: Factors Predictive of Prolonged Time Off Therapy. The Oncologist 5:1, pages 45-52.
Crossref
Crossref
Terrence Diamond, Joanne Campbell, Carl Bryant & William Lynch. (1998) The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer 83:8, pages 1561-1566.
Crossref
Crossref
IGOR SCHEPETKIN. (1997) Osteoclastic Bone Resorption: Normal and Pathological. Annals of the New York Academy of Sciences 832:1 Phagocytes, pages 170-193.
Crossref
Crossref
Arnon Krongrad, Silvina Levis & Bernard A. Roos. (1997) RE. The Journal of Urology, pages 1529-1530.
Crossref
Crossref
Manuel Fernández-Conde, Juan Alcover, Jean E. Aaron, Jaume Ordi & Pablo Carretero. (1997) Skeletal Response to Clodronate in Prostate Cancer with Bone Metastases. American Journal of Clinical Oncology 20:5, pages 471-476.
Crossref
Crossref
Arnon KrongradSilvina LevisBernard A. Roos. (1997) RE: OSTEOPOROSIS AFTER ORCHIECTOMY FOR PROSTATE CANCER. Journal of Urology 158:4, pages 1529-1530.
Crossref
Crossref
Harry W. Daniell. (1997) Osteoporosis After Orchiectomy for Prostate Cancer. The Journal of Urology, pages 439-444.
Crossref
Crossref
Harry W. Daniell. (1997) Osteoporosis After Orchiectomy for Prostate Cancer. Journal of Urology 157:2, pages 439-444.
Crossref
Crossref
Anthony H. Horan. (1996) Re. The Journal of Urology, pages 1395.
Crossref
Crossref
Anthony H. Horan. (1996) Re: Osteoporosis as a complication of Orchiectomy in 2 Elderly Men with Prostatic Cancer. Journal of Urology 155:4, pages 1395-1395.
Crossref
Crossref